Biostar Pharma Wins Patent for Second Hepatitis B Product

| About: Biostar Pharmaceutic (BSPM)

Biostar Pharmaceuticals, Inc. (NASDAQ:BSPM) received a China patent for Aoxing Ganbao, an external use TCM treatment for hepatitis B. Biostar already has name recognition in the hepatitis B sector with its flagship product, Xin Aoxing Oleanolic Acid Capsules. Xin Aoxing Oleanolic capsules, which is the only OTC oral hepatitis treatment product approved by the SFDA, generates about 50% of Biostar’s revenues.

The new product, Aoxing Ganbao, is applied topically to fight hepatitis B symptoms by nourishing the liver and reducing inflammation without side effects. Aoxing Ganbao is attached to the patient’s waist with herbs facing the navel. Each dose can be used for one month. Most patients use the product on a long-term basis because hepatitis B is a chronic condition.

Biostar said it would set the retail price of Aoxing Ganbao at approximately $20, where its gross margin will be 70%. The patent gives the product protection from competition for 20 years.

Biostar said it would continue to develop products for hepatitis B, which affects 10% of China’s population.

Disclosure: none.